Matrix metalloproteinases in colorectal cancer

Clinical Colorectal Cancer

Volumn 1, Issue 4, 2002, Pages 208-219

  Mysliwiec, Angela G ^a   Ornstein, Deborah L ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Collagenases; Gelatinases; Metastasis; Stromelysins

Indexed keywords

BATIMASTAT; COLLAGENASE; GELATINASE; KB R 7785; MACROPHAGE ELASTASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N1 (1 CARBAMOYL 2,2 DIMETHYLPROPYL) 2 [3 (4 CHLOROPHENYL)PROPYL] N4 HYDROXYBUTANEDIAMIDE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; EXTRACELLULAR MATRIX; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; MYALGIA; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 0036215831     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2002.n.002     Document Type: Review

References (112)

1. Cancer statistics, 2001
2. Metalloproteinases and cancer invasion
3. Loss of basement membrane components by invasive tumors but not by their benign counterparts
4. Laminin and fibronectin in rectal adenocarcinoma: Relationship to tumour grade, stage and metastasis
5. Tumour basement membrane laminin in adenocarcinoma of rectum: An immunohistochemical study of biological and clinical significance
6. Laminin expression in colorectal carcinomas varying in degree of differentiation
7. Proteolytic remodeling of extracellular matrix
8. Matrix metalloproteinases
9. Role of matrix metalloproteinases in normal and disease processes
10. Matrix metalloproteinases in tumor invasion
11. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis
12. Matrix metalloproteinases in tumor invasion and metastasis
13. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
14. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer
15. Matrix metalloproteinases: They're not just for matrix anymore!
16. Matrix metalloproteinases: Effectors of development and normal physiology
17. Matrix metalloproteinases of normal human tissues
18. Matrix metalloproteinases and metastasis
19. Matrix metalloproteinase inhibitors: Current developments and future perspectives
20. Matrix metalloprotenaises: Biologic activity and clinical implications
21. ECM and cell surface proteolysis: Regulating cellular ecology
22. Matrix metalloproteinase inhibitors
23. Mechanisms for pro matrix metalloproteinase activation
24. Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion
25. Membrane associated matrix metalloproteinases in metastasis
26. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression
27. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
28. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells
29. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms
30. Regulation of matrix metalloproteinases during extracellular matrix turnover
31. Cytokine regulation of metalloproteinase gene expression
32. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
33. Proteases and protease inhibitors in tumor progression
34. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface
35. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2
36. TIMP-2 expression modulates human melanoma cell adhesion and motility
37. How matrix metalloproteinases regulate cell behavior
38. Genes associated with embryonic attachment and implantation and the role of progesterone
39. Biochemistry and molecular biology of trophoblast invasion
40. Matrix metalloproteinases in wound repair (review)
41. Extracellular matrix remodeling in the vascular wall
42. Dynamics of cardiac wound healing following myocardial infarction: Observations in genetically altered mice
43. Cellular interactions in vascular growth and differentiation
44. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
45. Regulation of matrix metalloproteinase expression in tumor invasion
46. The role of metalloproteinases and their inhibitors in hematological disorders
47. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis
48. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging
49. Expression of matrix metalloproteinase-1 in human colorectal carcinoma
50. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer
51. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
52. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription
53. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness
54. Enhanced secretion and activation of matrilysin during malignant conversion of human colorectal epithelium and its relationship with invasive potential of colon cancer cells
55. Role of matrix metalloproteinases in colorectal carcinogenesis
56. Matrilysin in early stage intestinal tumorigenesis
57. Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers
58. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas
59. Detection of regional lymph node metastases in colon cancer by using RT-PCR for matrix metalloproteinase 7, matrilysin
60. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
61. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo
62. Matrilysin as a target for chemotherapy for colon cancer: Use of antisense oligonucleotides as antimetastatic agents
63. Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer
64. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans
65. Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas. Localization and clinicopathologic correlations
66. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes
67. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells
68. Metastasis of human colon tumor cells in vivo: Correlation with the overexpression of plasminogen activators and 72 kDa gelatinase
69. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis
70. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas
71. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas
72. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma
73. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer
74. Proteolysis in colorectal cancer
75. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy
76. Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer
77. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples
78. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon
79. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression
80. The expression of MMP-2 and TIMP-2 in patients with primary colorectal adenocarcinoma: Correlation with liver metastasis
81. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer
82. A prospective study of prognostic value of type IV collagenase activity in colorectal cancer tissue
83. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
84. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis
85. The balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium
86. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: Relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase
87. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy
88. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma
89. Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer
90. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases
91. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors
92. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer
93. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer
94. Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer
95. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage
96. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma
97. Tissue inhibitor of metalloproteinase-3 is a basement membrane-associated protein that is significantly decreased in human colorectal cancer
98. Development of matrix metalloproteinase inhibitors in cancer therapy
99. Clinical potential of matrix metalloproteinase inhibitors in cancer therapy
100. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
101. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
102. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model
103. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats
104. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor
105. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
106. Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro
107. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
108. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
109. Marimastat as firstline therapy for patients with unresectable pancreatic cancer: A randomized trial
110. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis
111. Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray
112. Genetic diversity in the matrix metalloproteinase family. Effects on function and disease progression